Peer-reviewed literature confirms IGF-1 LR3 is a recombinant analog studied for biological effects. PMID 37261455 (2023) demonstrates successful recombinant production of bioactive IGF-1 and LR3 IGF-1 in P. pastoris with confirmed cell proliferation bioactivity; PMID 16397250 (2006) documents IGF-1R inhibitor research showing LR3 IGF-I ligand involvement in cancer cell signaling pathways. While no FDA-approved therapeutic indication exists for LR3 IGF-1 in humans, the peptide is actively studied in research contexts and has documented biological mechanisms in peer-reviewed journals.

Both peptides have documented research pedigree. CJC-1295 has completed human Phase 2 clinical trials (Teichman SL et al., PMID 17213277, 2006) showing GH secretagogue effects. Ipamorelin similarly has human clinical trial data supporting GH secretagogue function. PeptIQ internal references confirm Phase 2 human trial completion for CJC-1295. Neither has FDA approval for therapeutic use, but both have progressed beyond preclinical stage into human studies, supporting the claim's direction that they are studied for therapeutic purposes.

Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials with published Phase 2 data (Jastreboff AM et al., NEJM 2023, PMID 37354027). As a GLP-1/GIP/glucagon receptor agonist, the mechanism directly targets glucose homeostasis pathways, and Phase 2 data documented metabolic and glycemic improvements. The TRIUMPH-4 Phase 3 trial (December 2025) reinforces active human investigation. Blood sugar balance is mechanistically aligned with GLP-1 agonist function and supported by published trial data.